Anti-Angiogenic Mushrooms: Strongest Species Ranked

Mushroom Anti-Angiogenesis

47+ species tested

At least 47 mushroom species have demonstrated some degree of anti-angiogenic activity in preclinical models, but the depth and quality of evidence varies enormously across species.

Multiple sources; Cao et al., 2004; Stanley et al., 2005

Ganoderma lucidum

most studied species for VEGF suppression

Ergosterol

first mushroom anti-angiogenic compound identified

0 clinical trials

no mushroom tested for anti-angiogenesis in humans

Multiple sources; Cao et al., 2004; Stanley et al., 2005

View as image ↗

Tumors cannot grow beyond a few millimeters without building their own blood supply. This process, angiogenesis, involves signaling molecules like VEGF (vascular endothelial growth factor) that recruit blood vessels to feed the growing tumor. Drugs that block angiogenesis (bevacizumab, sunitinib) are established cancer therapies. The question of whether mushroom compounds can do the same thing has driven over two decades of preclinical research across dozens of species.

The answer is nuanced. Multiple mushroom species suppress angiogenesis in cell culture and animal models, but the evidence varies from single proof-of-concept studies to systematic mechanistic work. This article ranks the five species with the strongest preclinical anti-angiogenic evidence, describes what each brings to the table, and identifies where the evidence falls short. For how this fits into the broader picture of tumor blood supply suppression, see mushroom anti-angiogenic compounds: starving tumors of their blood supply.

1. Ganoderma lucidum (reishi): the deepest evidence base

Reishi has the most extensive anti-angiogenic research of any mushroom species, with multiple studies examining different compound classes and mechanisms.

VEGF and TGF-beta1 suppression

Stanley et al. (2005) showed that Ganoderma lucidum extract suppressed secretion of both VEGF and TGF-beta1 from PC-3 prostate cancer cells. The mechanism involved inhibition of constitutively active AP-1 (activator protein-1), a transcription factor that drives expression of both angiogenic factors.^[1]

Upstream, Ganoderma lucidum modulated phosphorylation of both Erk1/2 and Akt kinases, which converge on AP-1 activity. The dual pathway inhibition (both MAPK/Erk and PI3K/Akt) suggests a broad mechanism rather than single-target action.^[1]

Polysaccharide-peptide anti-angiogenesis

Cao et al. (2004) tested Ganoderma lucidum polysaccharides peptide (GLPP) using two distinct in vivo angiogenesis models: the dorsal skinfold chamber in mice and the chick chorioallantoic membrane (CAM) assay.^[2]

GLPP inhibited VEGF-induced tube formation of human umbilical vein endothelial cells in vitro, and reduced new blood vessel growth in both in vivo models. The compound also directly inhibited endothelial cell proliferation and induced endothelial cell apoptosis, meaning it attacked angiogenesis from multiple angles: blocking the growth signal (VEGF), preventing endothelial cell division, and killing endothelial cells directly.^[2]

The combination of low-molecular-weight triterpenoid effects (Stanley et al.) and high-molecular-weight polysaccharide-peptide effects (Cao et al.) makes reishi unique among mushrooms: both its major compound classes show anti-angiogenic activity through different mechanisms.

A critical nuance: the triterpenoid studies used organic solvent extracts (which concentrate small molecules like ganoderic acids), while the polysaccharide studies used hot water or water-ethanol extracts (which concentrate large carbohydrate polymers). A commercial reishi product's anti-angiogenic potential depends entirely on which extraction method was used. A polysaccharide-focused extract targets different mechanisms than a triterpenoid-focused extract, and a generic "reishi extract" label tells a consumer nothing about which bioactive class dominates the preparation.

2. Agaricus blazei: where mushroom anti-angiogenesis research began

The first identification of a specific anti-angiogenic compound from any mushroom came from Agaricus blazei research.

Ergosterol: the pioneer compound

Takaku et al. (2001) isolated ergosterol from Agaricus blazei and showed it inhibited tumor growth in sarcoma 180-bearing mice at oral doses of 400 and 800 mg/kg for 20 days without side effects.^[3]

The anti-tumor mechanism was not direct cytotoxicity (ergosterol did not kill cancer cells in culture) but rather inhibition of tumor-induced neovascularization. At intraperitoneal doses of 5, 10, and 20 mg/kg for 5 days, ergosterol suppressed neovascularization induced by Lewis lung carcinoma cell-packed chambers. It also inhibited Matrigel-induced neovascularization when mixed with angiogenic growth factors, confirming direct anti-angiogenic activity rather than indirect immune effects.^[3]

This was the first demonstration that a mushroom compound could inhibit angiogenesis directly, and it established ergosterol as the mechanistic basis for Agaricus blazei's anti-tumor effects.

Sodium pyroglutamate: a second anti-angiogenic compound

Kimura et al. (2004) isolated a second anti-angiogenic substance from Agaricus blazei: sodium pyroglutamate (A-1). At oral doses of 30, 100, and 300 mg/kg, A-1 inhibited Lewis lung carcinoma tumor growth and lung metastasis.^[4]

The mechanism was multifaceted: A-1 increased apoptotic cells within tumors, increased CD8+ T cell and NK cell infiltration, and inhibited von Willebrand factor expression (a marker of angiogenesis) in tumors. The anti-angiogenic effect combined with immunostimulatory and pro-apoptotic activity in a single compound from a single mushroom species.^[4]

For more on how Agaricus blazei compounds interact with cancer biology, see Agaricus blazei and cancer: research from Brazil and Japan.

3. Phellinus linteus: Akt-mediated VEGF suppression

Phellinus linteus (also called Meshimakobu in Japan) is a wood-decay polypore used in traditional East Asian medicine. Sliva et al. (2008) published the most mechanistically detailed anti-angiogenic study for this species using highly invasive MDA-MB-231 breast cancer cells.^[5]

Phellinus linteus extract suppressed VEGF secretion from MDA-MB-231 cells in a dose-dependent manner. The mechanism traced to Akt kinase suppression: by inhibiting Akt phosphorylation, Phellinus linteus reduced VEGF transcription.^[5]

The anti-angiogenic effect extended to direct action on endothelial cells. Phellinus linteus inhibited capillary morphogenesis (tube formation) of endothelial cells both directly and indirectly through reduced VEGF secretion from cancer cells. It also suppressed invasive behavior through reduced urokinase-plasminogen activator secretion and induced cell cycle arrest at S phase through p27 upregulation.^[5]

The Akt pathway is the same node targeted by Ganoderma lucidum (Stanley et al., 2005), suggesting a common anti-angiogenic mechanism across phylogenetically distinct mushroom species.

4. Cantharellus cibarius (chanterelle): a lipoxygenase-mediated pathway

Marathe et al. (2022) identified a mechanistically distinct anti-angiogenic pathway in chanterelle mushrooms. Rather than targeting VEGF directly, Cantharellus cibarius extracts inhibited lipoxygenase enzymes, and the anti-angiogenic activity correlated with the degree of lipoxygenase inhibition.^[6]

Lipoxygenases produce pro-angiogenic eicosanoids from arachidonic acid. When lipoxygenase activity is blocked, the production of these angiogenesis-promoting lipid mediators decreases. This represents a non-VEGF pathway for anti-angiogenesis, mechanistically distinct from the Akt/VEGF suppression seen in reishi and Phellinus.^[6]

The practical significance is that chanterelle anti-angiogenic activity involves compounds commonly consumed in culinary contexts. Chanterelles are eaten worldwide as a food mushroom, raising the question of whether dietary exposure contributes any anti-angiogenic benefit. The answer is unknown and possibly unknowable from preclinical data alone, since the concentrations used in laboratory assays may not match those achieved through dietary intake.

5. Fomitopsis officinalis (agarikon): polysaccharide-driven effects

Shen et al. (2024) isolated a polysaccharide from Fomitopsis officinalis (agarikon, also known as quinine conk) that showed both immune-activating and anti-angiogenic properties in tumor models.^[7]

The anti-tumor effect involved dual mechanisms: activating innate immunity (increasing macrophage and NK cell activity) while simultaneously inhibiting tumor angiogenesis. The polysaccharide reduced VEGF expression in tumor tissue and suppressed new blood vessel formation in vivo.^[7]

Fomitopsis officinalis is an endangered species in many regions, making it a challenging candidate for therapeutic development. Paul Stamets and other mycologists have advocated for conservation efforts specifically because of the species' medicinal potential. However, the anti-angiogenic data is limited to a single polysaccharide fraction from a single study. The dual immune/anti-angiogenic mechanism parallels what was seen with Agaricus blazei's sodium pyroglutamate, suggesting this combination of activities may be more common among polypore mushrooms than currently appreciated. Whether agarikon polysaccharides are more or less potent than reishi polysaccharides for anti-angiogenic activity cannot be determined from the existing data, since different experimental systems were used.

Ranking the evidence

Comparing across species, the evidence stacks up roughly as follows:

Strongest evidence: Ganoderma lucidum. Multiple independent compound classes tested (triterpenoids, polysaccharides), multiple research groups, both in vitro and in vivo data, clear molecular pathways mapped (Erk/Akt/AP-1/VEGF). The species has the broadest evidence base by a considerable margin.

Strong mechanistic evidence: Phellinus linteus. Single detailed study but excellent mechanistic depth. Akt/VEGF pathway clearly established. Direct and indirect anti-angiogenic effects demonstrated.

Historical significance: Agaricus blazei. Two distinct anti-angiogenic compounds identified. In vivo data in tumor-bearing mice. Ergosterol finding was the first of its kind for any mushroom.

Emerging evidence: Cantharellus cibarius. Novel lipoxygenase mechanism. Limited to a single study. Interesting for identifying a non-VEGF pathway.

Preliminary: Fomitopsis officinalis. Polysaccharide-based effects. Single recent study. Conservation status limits practical application.

This ranking reflects the volume and mechanistic depth of published evidence, not a comparison of potency. Direct potency comparisons between species are not possible because studies used different cell lines, concentrations, extract preparations, and assay systems. For a comparison of mushroom vs. pharmaceutical anti-angiogenic approaches, see mushroom anti-angiogenesis vs. pharmaceutical approaches.

Why no mushroom has entered anti-angiogenesis clinical trials

The gap between preclinical anti-angiogenic data and human testing reflects structural challenges:

Extract complexity. Mushroom extracts contain hundreds of compounds. Identifying which specific molecules drive anti-angiogenic activity, at what dose, and with what pharmacokinetics, requires the kind of pharmaceutical investment that natural products rarely attract.

Existing competition. Bevacizumab (Avastin) and other anti-VEGF drugs already exist and have known efficacy, validated biomarkers, and established manufacturing processes. The regulatory path for a mushroom-derived anti-angiogenic agent would require demonstrating superiority or non-inferiority against established drugs, a high bar. The more realistic clinical pathway would be as an adjunct therapy (used alongside conventional treatment), but even this requires Phase I/II safety and dosing studies that no mushroom anti-angiogenic compound has undergone.

Standardization. The same species produces different compound profiles depending on growing conditions, extraction methods, and processing. Clinical trials require standardized, reproducible material, which remains difficult for mushroom-derived preparations.

No single champion. Unlike antroquinonol from Antrodia camphorata (which has entered lung cancer clinical trials as a single molecule), no mushroom anti-angiogenic compound has been developed as an isolated pharmaceutical candidate. Ergosterol from Agaricus blazei is the most structurally defined anti-angiogenic compound, but it is a ubiquitous fungal sterol found in many species, which limits intellectual property protection and commercial incentive for pharmaceutical development. For how VEGF inhibition works at the molecular level, see how mushroom compounds inhibit VEGF and tumor blood vessel growth.

The Bottom Line

Ganoderma lucidum (reishi) has the strongest preclinical evidence for anti-angiogenic activity among mushroom species, with both triterpenoid and polysaccharide compound classes suppressing VEGF and angiogenesis through Erk/Akt/AP-1 pathway inhibition. Agaricus blazei provided the first mushroom anti-angiogenic compound (ergosterol), Phellinus linteus targets the Akt/VEGF axis in breast cancer cells, chanterelles work through lipoxygenase inhibition, and agarikon combines anti-angiogenesis with immune activation. No mushroom species has been tested in human anti-angiogenesis trials.

Frequently Asked Questions

Which mushroom is most anti-angiogenic?

Ganoderma lucidum (reishi) has the broadest preclinical evidence for anti-angiogenic activity. Two major compound classes from reishi suppress angiogenesis: triterpenoids that inhibit VEGF and TGF-beta1 secretion through Erk/Akt/AP-1 suppression (Stanley et al., 2005), and polysaccharide-peptides that directly inhibit endothelial cell proliferation and tube formation (Cao et al., 2004). No head-to-head potency comparisons exist between mushroom species.

Can mushrooms stop tumor blood vessel growth?

In preclinical models, multiple mushroom species suppressed tumor-induced angiogenesis. Ergosterol from Agaricus blazei inhibited neovascularization in Lewis lung carcinoma mice at 5-20 mg/kg (Takaku et al., 2001). Ganoderma lucidum polysaccharides reduced blood vessel formation in dorsal skinfold chamber and chick embryo models (Cao et al., 2004). All evidence is from cell culture and animal models with no human clinical trials.

What mushroom compounds inhibit VEGF?

Multiple mushroom compounds suppress VEGF expression or secretion. Ganoderma lucidum triterpenoids reduce VEGF secretion through Akt and Erk pathway inhibition (Stanley et al., 2005). Phellinus linteus extracts suppress VEGF through Akt inhibition in breast cancer cells (Sliva et al., 2008). Fomitopsis officinalis polysaccharides reduce tumor VEGF expression in vivo (Shen et al., 2024). These are mechanistically diverse compounds targeting VEGF through different upstream pathways.

Is ergosterol from mushrooms anti-angiogenic?

Ergosterol isolated from Agaricus blazei was the first mushroom compound demonstrated to have anti-angiogenic activity. At intraperitoneal doses of 5-20 mg/kg, ergosterol inhibited neovascularization induced by Lewis lung carcinoma cells and by Matrigel supplemented with fibroblast growth factor (Takaku et al., 2001). Ergosterol did not kill cancer cells directly but reduced tumors by cutting off their blood supply. Ergosterol is found in many mushroom species, not just Agaricus blazei.

Do reishi mushrooms inhibit angiogenesis?

In preclinical research, Ganoderma lucidum (reishi) demonstrates anti-angiogenic activity through at least two mechanisms. Triterpenoid extracts suppress VEGF and TGF-beta1 secretion from prostate cancer cells via Erk/Akt/AP-1 inhibition (Stanley et al., 2005). Polysaccharide-peptide extracts directly inhibit endothelial cell proliferation and tube formation while reducing angiogenesis in animal models (Cao et al., 2004). No human clinical trials have tested reishi specifically for anti-angiogenic effects.

Are chanterelle mushrooms anti-angiogenic?

Cantharellus cibarius (chanterelle) extracts showed anti-angiogenic effects in a 2022 study, with the activity correlating to lipoxygenase inhibition rather than direct VEGF suppression (Marathe et al., 2022). This is a mechanistically distinct pathway from the Akt/VEGF axis targeted by reishi and Phellinus linteus. Whether the concentrations active in laboratory assays are achievable through dietary consumption of chanterelles is unknown.

Sources & References

1. 1RTHM-00087·Stanley, Gwenaelle et al. (2005). “Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells..” Biochemical and biophysical research communications.Study breakdown →PubMed →↩
2. 2RTHM-00067·Cao, Qi-Zhen et al. (2004). “Antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide..” Acta pharmacologica Sinica.Study breakdown →PubMed →↩
3. 3RTHM-00039·Takaku, T et al. (2001). “Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action..” The Journal of nutrition.Study breakdown →PubMed →↩
4. 4RTHM-00073·Kimura, Yoshiyuki et al. (2004). “Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions..” Cancer science.Study breakdown →PubMed →↩
5. 5RTHM-00271·Sliva, D et al. (2008). “Phellinus linteus Extract in Breast-Cancer Cell Models: What This 2008 Study Actually Found.” British journal of cancer.Study breakdown →PubMed →↩
6. 6RTHM-00786·Marathe, Sandesh J et al. (2022). “Anti-Angiogenic Effect of Cantharellus cibarius Extracts, its Correlation with Lipoxygenase Inhibition, and Role of the Bioactives Therein..” Nutrition and cancer.Study breakdown →PubMed →↩
7. 7RTHM-00907·Shen, Yongye et al. (2024). “An antitumor fungal polysaccharide from Fomitopsis officinalis by activating immunity and inhibiting angiogenesis..” International journal of biological macromolecules.Study breakdown →PubMed →↩